Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Insulin resistance in patients with cancer: a systematic review and meta-analysis

Insulin resistance in patients with cancer: a systematic review and meta-analysis Abstract Background Insulin resistance is a critical cause of metabolic dysfunctions. Metabolic dysfunction is common in patients with cancer and is associated with higher cancer recurrence rates and reduced overall survival. Yet, insulin resistance is rarely considered in the clinic and thus it is uncertain how frequently this condition occurs in patients with cancer. Methods To address this knowledge gap, we performed a systematic review and a meta-analysis guided by the Preferred Items for Systematic Review and Meta-Analyses (PRISMA) statement. We included studies assessing insulin resistance in patients with various cancer diagnoses, using the gold-standard hyperinsulinemic–euglycemic clamp method. Studies eligible for inclusion were as follows: (1) included cancer patients older than 18 years of age; (2) included an age-matched control group consisting of individuals without cancer or other types of neoplasms; (3) measured insulin sensitivity using the hyperinsulinemic–euglycemic clamp method. We searched the databases MEDLINE, Embase, and Cochrane Central Register of Controlled Trials for articles published from database inception through March 2023 with no language restriction, supplemented by backward and forward citation searching. Bias was assessed using funnel plot. Findings Fifteen studies satisfied the criteria. The mean insulin-stimulated rate of glucose disposal (Rd) was 7.5 mg/kg/min in control subjects (n = 154), and 4.7 mg/kg/min in patients with a cancer diagnosis (n = 187). Thus, the Rd mean difference was −2.61 mg/kg/min [95% confidence interval, −3.04; −2.19], p<.01). Heterogeneity among the included studies was insignificant (p=.24). Interpretation These findings suggest that patients with a cancer diagnosis are markedly insulin resistant. As metabolic dysfunction in patients with cancer associates with increased recurrence and reduced overall survival, future studies should address if ameliorating insulin resistance in this population can improve these outcomes thereby improving patient care. Key points Metabolic dysfunction increases cancer recurrence rates and reduces survival for patients with cancer. Insulin resistance is a critical cause of metabolic dysfunctions. To date, no comprehensive compilation of research investigating insulin resistance in cancer patients has been produced. In this meta-analysis, we found that patients with various cancers were markedly insulin-resistant. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Oncologica Taylor & Francis

Insulin resistance in patients with cancer: a systematic review and meta-analysis

Download PDF
8 pages

Loading next page...
 
/lp/taylor-francis/insulin-resistance-in-patients-with-cancer-a-systematic-review-and-DxPzeVY6f0

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Taylor & Francis
Copyright
© 2023 Acta Oncologica Foundation
ISSN
1651-226X
eISSN
0284-186X
DOI
10.1080/0284186X.2023.2197124
Publisher site
See Article on Publisher Site

Abstract

Abstract Background Insulin resistance is a critical cause of metabolic dysfunctions. Metabolic dysfunction is common in patients with cancer and is associated with higher cancer recurrence rates and reduced overall survival. Yet, insulin resistance is rarely considered in the clinic and thus it is uncertain how frequently this condition occurs in patients with cancer. Methods To address this knowledge gap, we performed a systematic review and a meta-analysis guided by the Preferred Items for Systematic Review and Meta-Analyses (PRISMA) statement. We included studies assessing insulin resistance in patients with various cancer diagnoses, using the gold-standard hyperinsulinemic–euglycemic clamp method. Studies eligible for inclusion were as follows: (1) included cancer patients older than 18 years of age; (2) included an age-matched control group consisting of individuals without cancer or other types of neoplasms; (3) measured insulin sensitivity using the hyperinsulinemic–euglycemic clamp method. We searched the databases MEDLINE, Embase, and Cochrane Central Register of Controlled Trials for articles published from database inception through March 2023 with no language restriction, supplemented by backward and forward citation searching. Bias was assessed using funnel plot. Findings Fifteen studies satisfied the criteria. The mean insulin-stimulated rate of glucose disposal (Rd) was 7.5 mg/kg/min in control subjects (n = 154), and 4.7 mg/kg/min in patients with a cancer diagnosis (n = 187). Thus, the Rd mean difference was −2.61 mg/kg/min [95% confidence interval, −3.04; −2.19], p<.01). Heterogeneity among the included studies was insignificant (p=.24). Interpretation These findings suggest that patients with a cancer diagnosis are markedly insulin resistant. As metabolic dysfunction in patients with cancer associates with increased recurrence and reduced overall survival, future studies should address if ameliorating insulin resistance in this population can improve these outcomes thereby improving patient care. Key points Metabolic dysfunction increases cancer recurrence rates and reduces survival for patients with cancer. Insulin resistance is a critical cause of metabolic dysfunctions. To date, no comprehensive compilation of research investigating insulin resistance in cancer patients has been produced. In this meta-analysis, we found that patients with various cancers were markedly insulin-resistant.

Journal

Acta Oncologica – Taylor & Francis

Published: Apr 3, 2023

Keywords: Cancer; insulin resistance; metabolic dysfunction; hyperinsulinemic–euglycemic clamp; systematic review; meta-analysis

References

  • Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
  • Prospective study of hyperglycemia and cancer risk
  • Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults
  • Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults
  • Endogenous hyperinsulinemia contributes to pancreatic cancer development
  • Daily insulin dose and cancer risk among patients with type 1 diabetes
  • Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study
  • Defining insulin resistance from hyperinsulinemic–euglycemic clamps
  • Skeletal muscle insulin resistance is the primary defect in type 2 diabetes
  • Molecular mechanisms in skeletal muscle underlying insulin resistance in women who are lean with polycystic ovary syndrome
  • NAFLD and diabetes mellitus
  • Insulin resistance and coronary artery disease
  • The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
  • Citationchaser: a tool for transparent and efficient forward and backward citation chasing in systematic searching
  • Glucose clamp technique: a method for quantifying insulin secretion and resistance
  • Insulin action and metabolism in patients with head and neck cancer
  • Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin
  • Insulin secretion and action in patients with pancreatic cancer
  • In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma
  • Reduced non-oxidative glucose utilization in cancer patients is associated with a low triiodothyronine concentration
  • Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia
  • The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia
  • Insulin resistance in patients with colorectal cancer
  • Reduced insulin sensitivity in differentiated thyroid cancer patients with suppressed TSH
  • Protein, glucose and lipid metabolism in the cancer cachexia: a preliminary report
  • Effect of systemic hyperinsulinemia in cancer patients
  • Circulating interleukin 6 concentrations and insulin resistance in patients with cancer
  • Serum tumour necrosis factor alpha and insulin resistance in gastrointestinal cancer
  • Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure
  • Insulin resistance was connected with the alterations of substrate utilization in patients with cancer
  • Effects of tumor removal and body weight loss on insulin resistance in patients with cancer
  • The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia
  • Incidence of new-onset type 2 diabetes after cancer: a Danish Cohort Study
  • Incidence of diabetes after cancer development: a Korean National Cohort Study
  • Obesity and cancer—mechanisms underlying tumour progression and recurrence
  • Diabetes and cancer: a consensus report
  • Cardiovascular disease, cancer, and multimorbidity interactions: clinical implications
  • Cancer cachexia: mediators, signaling, and metabolic pathways
  • The role of insulin resistance in the development of muscle wasting during cancer cachexia
  • Circulating follistatin and activin A and their regulation by insulin in obesity and type 2 diabetes
  • Cancer causes metabolic perturbations associated with reduced insulin-stimulated glucose uptake in peripheral tissues and impaired muscle microvascular perfusion
  • Cancer causes dysfunctional insulin signaling and glucose transport in a muscle-type-specific manner
  • Cancer-drug induced insulin resistance: innocent bystander or unusual suspect
  • Acute hyperglycemia associated with anti-cancer medication
  • Glucocorticoid-induced hyperglycemia
  • The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression
  • Adiposity and cancer risk: new mechanistic insights from epidemiology
  • Exercise—a panacea of metabolic dysregulation in cancer: physiological and molecular insights
  • Current advances in our understanding of exercise as medicine in metabolic disease
  • Exercise is medicine in oncology: engaging clinicians to help patients move through cancer
  • Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study
  • Low physical activity levels and functional decline in individuals with lung cancer